Navigation Links
Enbrel and Humira Remain the Mainstay for First-Line Biologic Rheumatoid Arthritis Treatment
Date:9/19/2013

progression of structural damage."

The recently published report also finds that treating rheumatologists would consider switching over half of their patients who are currently treated with Genentech's Actemra IV to the subcutaneous formulation of Actemra if it were commercially available.  Moreover, treating physicians would consider switching 22-34 percent of their patients currently treated with Orencia IV and 20-25 percent of their patients who are treated with Genentech/Biogen Idec's Rituxan or Janssen Biotech's Simponi to subcutaneous Actemra, Incyte/Eli Lilly's baricitinib, Sanofi/Regeneron's sarilumab or GlaxoSmithKline/Janssen Biotech's sirukumab, if these agents were on the market.

ChartTrends®: Rheumatoid Arthritis (US) is a quantitative publication based on patient audit data collected from 983 biologic- or Xeljanz-treated RA patient charts provided by 217 rheumatologists in May - June 2013 in the United States. Through an in-depth review of specific patient charts, details such as product dosing and titration, switching, concomitant medications and a host of laboratory and patient demographic variables help define patient types and identify therapy triggers. Requirements for the patient charts include: at least 18 years of age and less than 90 years of age, currently on one of the FDA-approved biologic agents for RA or Xeljanz, and under the rheumatologist's personal management for at least six months. All collection methods were designed in compliance with HIPAA.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at ww
'/>"/>

SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Enbrel® (etanercept) Patent Issued
2. Pittcon Announces Exhibiting Schedule for Remainder of 2013
3. Despite Lucentiss Recent Expanded Label for Diabetic Macular Edema, Avastin Remains the Preferred Intravitreal Therapy for Diabetic Macular Edema in the United States
4. Pesticide-Exempt Bed Bug Spray Samples Offered to Northern California Residents as Bed Bugs Remain a Trouble in the Area
5. Synthetic Biologics Reiterates that the Infectious Disease Collaboration with Intrexon Remains in Effect
6. ARAMARK Introduces Worlds First Reusable Validated Sterile Goggle That Remains Clear When Irradiated
7. New Way to Kill Bed Bugs Discovered; Bed Bug Bully Says Use of Bed Bug Spray Remains the Better Technique to Kill the Pests
8. Mold from Sandy Remains a Problem in Rockaways; My Cleaning Products Reaches Out to Help with Its Green Mold Removal Spray
9. Carin Grings remains identified by researchers at Uppsala University
10. 91 EnTERPreneurs Enter, Nine Remain
11. Cell Therapeutics Retires Remaining Convertible Debt
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014 Product and ... very low abundance and are often “lost in ... time-consuming. , Join presenters Dr. Rowel Tobias, Senior ... John Anders, Head of Quality at Nanotherapeutics, Inc., ... that can speed detection and quantitation while achieving ...
(Date:7/10/2014)... Understanding the need for better quality and higher ... that currently exists in this area, ChanTest has recently ... validated ion channel and GPCR cell lines. ChanTest’s ... channels control many critical physiological functions throughout the body. ... to treat a variety of human diseases. , ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Unraveling ... closer together. The Archer Family purchased a ... within DNA, but ended up with a lifetime of ... contained within the family members’ DNA genuinely brought the ... decided to search deeper into genetic history and prior ...
(Date:7/10/2014)... 10, 2014 OMICS Group’s 5th International ... 18-20 August, 2014 at Double Tree by Hilton Beijing, ... developments in Analytical & Bioanalytical research methods only to ... on this occasion, Dr. Srinubabu Gedela, MD of OMICS ... is a remarkable one in bringing a unique and ...
Breaking Biology Technology:Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4
... MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, ... and bioimplants processed from human amniotic membrane, announced ... Annual Canaccord Genuity Cardiovascular, Aesthetics and Metabolic Disorders ... Petit, Chairman and CEO, William C. Taylor, President ...
... and TORONTO, Dec. 1, 2011 Generex Biotechnology Corporation ... on the status of the clinical and regulatory ... insulin spray product. Work has been ... analyses), and revising all of the extant Generex ...
... Calif., Dec. 1, 2011  VIVUS, Inc. (NASDAQ: VVUS ... present an overview of the company at the 2011 Deutsche ... place at the Four Seasons Hotel, Boston, MA on Tuesday, ... and 30-day archive of the presentation will be available at ...
Cached Biology Technology:Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program 2Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program 3Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program 4VIVUS to Present at the Deutsche Bank BioFEST Conference 2VIVUS to Present at the Deutsche Bank BioFEST Conference 3
(Date:7/11/2014)... German . ... refraction of X-rays through a specimen instead of attenuation ... are often of much higher quality than those based ... Franz Pfeiffer are particularly interested in developing new approaches ... phase-contrast imaging. One main goal is to make this ...
(Date:7/11/2014)... National Institute of Standards and Technology (NIST) need ... effectively, they often prove that necessity is truly ... recently for M. Lorna De Leoz and Stephen ... of glycomics. Glycomics is the study of the ... attached to proteins and lipids and influence cellular ...
(Date:7/11/2014)... China Researchers from Salk Institute for Biological Studies, ... evaluated the safety and reliability of the existing ... new method, TALEN-HDAdV, which could significantly increased gene-correction ... This study published online in Cell Stell ... stem cell-based gene therapy. , The combination of ...
Breaking Biology News(10 mins):New simple setup for X-ray phase contrast 2A new genome editing method brings the possibility of gene therapies closer to reality 2
... target for a drug seems very promising on paper; ... of telomerase inhibitors,to treat cancer; they are supposed to ... cells. Yet, something in the cell,seems to block their ... do then? Scrap the project? Look for something,else? Hell ...
... in humans in forests between Gabon and the Republic ... animal carcasses, according to a study by the Wildlife ... the February edition of the journal Emerging Infectious Diseases, ... Ebola between 2001 and 2003 produced positive results, and ...
... by human activity and the extinction of species around ... warns a Canadian zoologist. This ecological damage also endangers ... , Dr. Daniel (Dan) Brooks, a parasitologist at the ... is linked to the emergence of new human and ...
Cached Biology News:Combination therapy boosts effectiveness of telomere-directed cancer cell death 2Study Links Ebola Outbreaks To Animal Carcasses 2Ecological destruction fuels emerging diseases 2
Mouse monoclonal [6911] to E. coli K99 pilus ( Abpromise for all tested applications)....
...
... genetically encoded fluorescent sensor capable for high ... one of the main ROS generated by ... fluorescent protein inserted into the regulatory domain ... demonstrates submicromolar affinity to H2O2 and at ...
Alexa Fluor 647 anti-mouse Qa-2...
Biology Products: